Investor Confidence Wanes as Oncoclínicas Reports 97.9% Decline in Net Income

Oncoclínicas (ONCO3), a major player in Brazil’s oncology sector, has faced a significant decline in its stock price. Even after reporting its first positive cash flow in several quarters, investor confidence remains shaky.

As of November 13, 2024, Oncoclínicas’ shares fell by 6.97%, trading at approximately R$ 4.14. This decline continues a troubling trend, with the stock losing about 67% of its value year-to-date.

The company’s third-quarter results disappointed analysts. They expected better performance, especially regarding profitability. The net income plummeted by 97.9% year-over-year, totaling just R$ 3.1 million ($544,000). This sharp decline stemmed from lower operational leverage, rising expenses, and a higher effective tax rate.

Despite these challenges, Oncoclínicas reported a positive free cash flow of R$ 20.3 million ($3.56) for Q3 2024. This marked a turnaround from previous quarters characterized by cash burn. Improved collection processes and better working capital management contributed to this positive cash flow.

However, this figure does not include various factors such as debt movements and capital expenditures related to acquisitions. The company indicated that cash generation improved due to enhanced collection from health plans and reduced capital spending.

In terms of revenue, Oncoclínicas experienced a 16.6% increase in net revenue for Q3 2024, reaching R$ 1.63 billion ($286 million). This growth resulted from a 7.9% rise in procedure volumes and a 4.9% increase in the average ticket price within its oncology segment.

The adjusted EBITDA also rose by 8.3%, totaling R$ 309 million ($54 million) compared to the same quarter last year. Despite these gains in revenue and EBITDA, the company’s net debt increased to R$ 3 billion ($526 million) by the end of Q3.

Operational costs rose significantly during this period. The total cost of services reached R$ 1.1 billion ($193 million), representing a year-over-year deterioration of 19.6%. This amount accounted for 62.1% of gross revenue.

Investor Confidence Wanes as Oncoclínicas Reports 97.9% Decline in Net Income

Investment firms like BTG Pactual have highlighted key concerns: slowing revenue growth, pressure on margins due to decreased operational leverage, and rising net debt levels. They maintain a neutral recommendation for ONCO3 shares with a target price of R$ 8.50 ($1.49) over the next year.

JP Morgan analysts echoed these sentiments, noting that the company’s stock trades at around 12 times its price-to-earnings ratio for 2025 while holding a neutral outlook on its shares.

Looking ahead, analysts suggest that Oncoclínicas must demonstrate improved capital discipline and clearer signs of deleveraging for investors to regain confidence. The recent focus on higher-quality payers could slow growth but may lead to better long-term profitability if managed effectively.

Goldman Sachs remains cautiously optimistic about Oncoclínicas’ future despite current challenges. They maintain a buy recommendation with a target price of R$ 9 ($1.58) for the next twelve months.

In summary, Oncoclínicas has made strides in generating cash flow and increasing revenues. However, significant operational challenges and high debt levels continue to weigh heavily on investor sentiment and stock performance. The company’s ability to navigate these issues will be crucial for restoring market confidence moving forward.

LatAm Markets: Live Signals → — real-time movers, turnover leaders and FX across Latin America.